Phase 2Completed
A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children
A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age
- Sponsor
- Tibotec Pharmaceuticals, Ireland (Industry)
- Enrollment
- 27 enrolled
- Conditions
- Human Immunodeficiency Virus 1
- Interventions
- Darunavir; Ritonavir
- Ages
- children
- Registry
- NCT00919854
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced Human immunodeficiency virus 1 (HIV 1) infected children.
Primary outcomes
- Number of Participants With Virological Response (Viral Load Less Than 50 Copies/mL) at Week 24 - Time to Loss of Virologic Response (TLOVR)
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered